• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1199010 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
* @# ~+ W5 `5 W3 A, t& ZNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # F" D" S! _& d
+ Author Affiliations
' d: E. x" _, q% L& I
# y  }' x- f' K2 d: C; K5 U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 9 z& E) {( ~1 T
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan . T5 x+ y- P! s3 J) X
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
% x! x" N, G& m) e6 p2 H+ |4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 6 k8 D% t' _6 h4 N' O& s8 H; p1 G
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ( F9 }: f/ p  L8 ~
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
' W$ u' I+ M) p7 r' t7Kinki University School of Medicine, Osaka 589-8511, Japan
( G2 S+ h2 F' S8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 i# _* M3 c. w
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan + _7 J$ q! p2 k' T7 V  }, q
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
& A$ b* y6 K8 W  p6 g+ _& H# {AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ( t$ t  N, H6 I2 u% y) w5 J

2 E4 r, Y& f' J* l" g2 U
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type % c2 G% v/ C0 Y) a- O  k, ~# L5 s
$ E# n. S' y  x
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
9 i7 V8 u. n5 t* e1 ?2 g5 `( ]) O8 @: e. A
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
5 m- v. D: _, J( B5 G. {' `$ X' L. j, ]3 ^" r6 D
Published online on: Thursday, December 1, 2011 5 S9 h& F  u9 ^5 W

( I% M; v3 H! ?4 tDoi: 10.3892/ol.2011.507 * X. l4 s5 `3 U- p6 r( K
% }+ _- T1 x3 c' }* ^6 K! X
Pages: 405-410
' t/ k" n3 b) y  J: l0 F* T; h) o3 z) ]! D
Abstract:
* @7 Q3 i( J# H) y1 aS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.0 U1 j- R, \4 G- C, G% c
. m& O! s; ~2 Z$ }
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
  I: y% i) \8 g3 N' q4 ]& ^5 W1 JF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 " S7 R& U6 @5 q' _5 y% P
+ Author Affiliations
0 K0 T8 |; Z6 \4 J, D% i  _$ E2 `1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
% G5 w1 T6 I1 U2 {) W2Department of Thoracic Surgery, Kyoto University, Kyoto
- e: |! [; I8 `, a3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
  Y. W! ^. _* }' {&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
: y! U, N+ G2 a  C" C" v0 c! WReceived September 3, 2010. * Z1 X  u& Y% \$ v: W" {& K% M
Revision received November 11, 2010.
% E" ~- M/ q6 z! WAccepted November 17, 2010. 7 n4 o' f# O( d% s
Abstract
3 S) r4 C+ b, _* d" Z5 SBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
! b: G4 D. f; DPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. / F  c7 B4 ?; p8 Y+ v) F5 _
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
( k! N) t( }  F: HConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 5 U& p3 h5 j7 P4 j2 ], t) L
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
) l. x7 ~* a9 E* [9 B今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?1 ?  r# N* M5 a1 t1 k
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
% K3 V' y  z, z( G, S- ehttp://clinicaltrials.gov/ct2/show/NCT01523587+ ^' M4 n5 [( l8 z8 Q4 n! A
% N1 ]% {6 p/ I4 ^' U
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
' h2 o& t% P6 t5 L$ ^9 }http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
  L; p: B4 [# Y& ]0 H  K3 L& [* s. t4 E9 z9 a5 i) f1 n6 Z
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。$ M# e1 F: a5 z& y; B2 j$ j7 S
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

/ k0 i, x3 v2 b8 q' f没有副作用是第一追求,效果显著是第二追求。5 b' P1 o1 [  o7 j( m3 }) A3 |
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表